189 related articles for article (PubMed ID: 23425901)
1. [Advances on driver oncogenes of lung adenocarcinoma].
Wang J; Zhang Z; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 Feb; 16(2):91-6. PubMed ID: 23425901
[TBL] [Abstract][Full Text] [Related]
2. [Advances on driver oncogenes of squamous cell lung cancer].
Hong W; Zhang Y
Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):433-6. PubMed ID: 24854563
[TBL] [Abstract][Full Text] [Related]
3. [Advances on driver oncogenes of non-small cell lung cancer].
Zhao J; Xiong J
Zhongguo Fei Ai Za Zhi; 2015 Jan; 18(1):42-7. PubMed ID: 25603872
[TBL] [Abstract][Full Text] [Related]
4. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
5. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Bronte G; Rizzo S; La Paglia L; Adamo V; Siragusa S; Ficorella C; Santini D; Bazan V; Colucci G; Gebbia N; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S21-9. PubMed ID: 21129606
[TBL] [Abstract][Full Text] [Related]
6. Molecular biomarkers for lung adenocarcinoma.
Calvayrac O; Pradines A; Pons E; Mazières J; Guibert N
Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28381431
[TBL] [Abstract][Full Text] [Related]
7. Gene aberrations for precision medicine against lung adenocarcinoma.
Saito M; Shiraishi K; Kunitoh H; Takenoshita S; Yokota J; Kohno T
Cancer Sci; 2016 Jun; 107(6):713-20. PubMed ID: 27027665
[TBL] [Abstract][Full Text] [Related]
8. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
[TBL] [Abstract][Full Text] [Related]
9. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network
Nature; 2014 Jul; 511(7511):543-50. PubMed ID: 25079552
[TBL] [Abstract][Full Text] [Related]
11. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
Duruisseaux M; McLeer-Florin A; Antoine M; Alavizadeh S; Poulot V; Lacave R; Rabbe N; Cadranel J; Wislez M
Cancer Med; 2016 Dec; 5(12):3579-3585. PubMed ID: 27770508
[TBL] [Abstract][Full Text] [Related]
12. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
[TBL] [Abstract][Full Text] [Related]
13. p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.
Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
Oncogene; 2013 Feb; 32(8):1050-8. PubMed ID: 22450744
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.
Oxnard GR; Nguyen KS; Costa DB
J Natl Cancer Inst; 2014 Jan; 106(1):djt361. PubMed ID: 24317178
[No Abstract] [Full Text] [Related]
15. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K; Tomizawa K; Mitsudomi T
Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
[TBL] [Abstract][Full Text] [Related]
16. Smad3-related miRNAs regulated oncogenic TRIB2 promoter activity to effectively suppress lung adenocarcinoma growth.
Zhang YX; Yan YF; Liu YM; Li YJ; Zhang HH; Pang M; Hu JX; Zhao W; Xie N; Zhou L; Wang PY; Xie SY
Cell Death Dis; 2016 Dec; 7(12):e2528. PubMed ID: 28005074
[TBL] [Abstract][Full Text] [Related]
17. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer pathogenesis and poor response to therapy were dependent on driver oncogenic mutations.
Sun X; Li K; Zhao R; Sun Y; Xu J; Peng ZY; Song RD; Ren H; Tang SC
Life Sci; 2021 Jan; 265():118797. PubMed ID: 33285162
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
20. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]